“Recent studies suggest that prophylaxis with Lacticaseibacillus​ species specifically can prevent the development of upper and lower RTIs in healthy subjects…Thus, modulation of the gut microbiome via probiotics is a promising strategy for prophylaxis and mitigation of Covid-19,” the researchers wrote. 

The Lacticaseibacillus rhamnosus​ GG (LGG) is particularly encouraging given the success of Lacticaseibacillus​ strains in numerous in vivo​ studies and clinical trials in healthy subjects, they added.

As Covid-19 continues to pose a global health challenge, research is showing a potentially significant role of the microbiome and dysbiosis in disease severity and development of long-Covid and “studies evaluating the role of probiotics and other methods of microbiome optimization are urgently needed,” the scientists noted. “Probiotics may be a low-risk, low-cost and easily implementable modality to reduce risk of Covid-19.”

However, the researchers reiterated that vaccination should remain the first line in the prevention of the disease. 

Study details​

To investigate the efficacy of the probiotic LGG as a post-exposure prophylaxis against Covid-19, 182 participants were enrolled in the study and took either LGG or placebo once daily for 28 days. The LGG capsules, made by Culturelle (DSM), contained ten billion colony forming units of the strain.

Additionally, participants needed to be exposed to a household contact diagnosed with Covid-19.

Enrollment began on June 24, 2020 and was stopped early on June 2, 2021, when most individuals approached for the study reported already been vaccinated and were therefore ineligible.

Source link